294 related articles for article (PubMed ID: 27272454)
1. Up-to-date tools for risk assessment before allogeneic hematopoietic cell transplantation.
Elsawy M; Sorror ML
Bone Marrow Transplant; 2016 Oct; 51(10):1283-1300. PubMed ID: 27272454
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
[TBL] [Abstract][Full Text] [Related]
3. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources.
Elsawy M; Storer BE; Milano F; Sandmaier BM; Delaney C; Salit RB; Rashad AH; Woolfrey AE; Appelbaum FR; Storb R; Sorror ML
Biol Blood Marrow Transplant; 2019 May; 25(5):1045-1052. PubMed ID: 30500442
[TBL] [Abstract][Full Text] [Related]
7. Refinement of the Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Ushiki T; Fuse K; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
Int J Hematol; 2018 Sep; 108(3):282-289. PubMed ID: 29744806
[TBL] [Abstract][Full Text] [Related]
8. Impact of Pretransplantation Indices in Hematopoietic Stem Cell Transplantation: Knowledge of Center-Specific Outcome Data Is Pivotal before Making Index-Based Decisions.
Törlén J; Remberger M; Le Blanc K; Ljungman P; Mattsson J
Biol Blood Marrow Transplant; 2017 Apr; 23(4):677-683. PubMed ID: 28063962
[TBL] [Abstract][Full Text] [Related]
9. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
10. The Glasgow Prognostic Score as a pre-transplant risk assessment for allogeneic hematopoietic cell transplantation.
Shibasaki Y; Suwabe T; Katagiri T; Tanaka T; Kobayashi H; Fuse K; Ushiki T; Sato N; Yano T; Kuroha T; Hashimoto S; Narita M; Furukawa T; Sone H; Masuko M
Clin Transplant; 2017 Nov; 31(11):. PubMed ID: 28871665
[TBL] [Abstract][Full Text] [Related]
11. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
[TBL] [Abstract][Full Text] [Related]
13. What the internist should know about stem cell transplant in the elderly patient.
Medinger M; Passweg J
Eur J Intern Med; 2018 Dec; 58():43-47. PubMed ID: 29960832
[TBL] [Abstract][Full Text] [Related]
14. Validation of the European Group for Blood and Marrow Transplantation (EBMT) risk score in patients receiving allogeneic hematopoietic stem cell transplantation at a single center in Japan.
Numata A; Tanaka M; Matsumoto K; Takasaki H; Tachibana T; Fujimaki K; Sakai R; Fujisawa S; Tomita N; Fujita H; Maruta A; Ishigatsubo Y; Kanamori H
Clin Transplant; 2014 Apr; 28(4):403-9. PubMed ID: 24655161
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902).
Wood WA; Le-Rademacher J; Syrjala KL; Jim H; Jacobsen PB; Knight JM; Abidi MH; Wingard JR; Majhail NS; Geller NL; Rizzo JD; Fei M; Wu J; Horowitz MM; Lee SJ
Cancer; 2016 Jan; 122(1):91-8. PubMed ID: 26439325
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of disease risk comorbidity index for overall survival after allogeneic hematopoietic transplantation.
Bejanyan N; Brunstein CG; Cao Q; Lazaryan A; Ustun C; Warlick ED; Arora M; Wagner JE; Weisdorf DJ
Blood Adv; 2019 Feb; 3(3):230-236. PubMed ID: 30674457
[TBL] [Abstract][Full Text] [Related]
17. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
18. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
[TBL] [Abstract][Full Text] [Related]
19. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
[TBL] [Abstract][Full Text] [Related]
20. Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants.
Passweg JR; Walker I; Sobocinski KA; Klein JP; Horowitz MM; Giralt SA;
Br J Haematol; 2004 Jun; 125(5):613-20. PubMed ID: 15147377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
